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Abstract: The primary objective of this study was to compare the effectiveness of combination 
treatment of valproate and amisulpride with that of valproate and haloperidol in bipolar I disorder. 
Adult inpatients with a current manic episode fulﬁ  lling DSM-IV-TR diagnostic criteria for bipolar 
type I disorder were included. Patients were randomized to amisulpride (400–800 mg/day) or 
haloperidol (5–15 mg/day) for 3 months and all received valproate. The primary effectiveness 
criterion was the percentage of responders (deﬁ  ned by a decrease of 50% of the Y-MRS) in 
patients completing the study. Safety was evaluated by adverse event reporting, determination 
of extrapyramidal function and clinical examination. Sixty-two patients were randomized to 
receive valproate-amisulpride, and 61 to receive valproate-haloperidol. At study end, responder 
rates were 72.6% in the amisulpride group and 65.5% in the haloperidol group. Remission rates 
were 83.9% and 89.7%, respectively. At study end, neither response rates nor remission rates 
differed signiﬁ  cantly between groups. Treatment-emergent adverse events occurred signiﬁ  -
cantly (p = 0.009) more frequently in the haloperidol group (86.4%) than in the amisulpride 
group (66.1%). In conclusion, the valproate–amisulpride combination was as effective as the 
valproate – haloperidol combination in bipolar I patients, with a better safety proﬁ  le.
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Introduction
Bipolar I disorder is an episodic, lifelong illness characterized by alternating phases 
of mania and depression. The lifetime prevalence of bipolar type I disorder estimated 
in general population surveys conducted in Europe ranges from 0.3% to 1.8% (Pini 
et al 2005). Bipolar disorder carries with it an increased risk of psychiatric or somatic 
morbidity (Krishnan 2005), substance abuse (Levin and Hennessy 2004), and suicide 
(Angst et al 2005), and is highly detrimental to stable social functioning (Elgie and 
Morselli 2007).
Current practice guidelines recommend ﬁ  rst-line treatment of acute mania with 
either lithium, valproate, or an atypical antipsychotic (APA 2002; Goodwin 2003; 
Grunze et al 2003). As monotherapy, atypical antipsychotics show similar efﬁ  cacy to 
mood stabilizers (lithium or valproate) (Smith et al 2007), whereas combination of the 
two classes of drug brings superior efﬁ  cacy (Scherk et al 2007) and is considered useful 
in cases of severe mania or inadequate response to monotherapy. Combining antipsy-
chotic drugs with lithium or valproate achieves a more rapid onset of response, better 
control of agitation and insomnia, and a lower risk of rebound depression (Bowden 
2005; Scherk et al 2007). Although haloperidol has been used widely for the acute 
treatment of mania, its use is associated with a higher incidence of extrapyramidal Neuropsychiatric Disease and Treatment 2008:4(3) 676
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effects than the more recent atypicals and may carry a higher 
risk of switch to depression and poor adherence (Tohen et al 
2003; Smulevich et al 2005).
Nonetheless, few randomized clinical trials have com-
pared atypical with classical antipsychotics in the treatment 
of acute mania. Sachs and colleagues (Sachs et al 2002) 
compared treatment with a combination of haloperidol and 
a mood-stabilizer with a combination of risperidone and a 
mood stabilizer and to a mood stabilizer alone in a 3-week 
study. Both antipsychotic combinations were superior to 
mood stabilizer alone in terms of symptomatic control of 
mania, with no signiﬁ  cant difference being observed between 
them. However, extrapyramidal side-effects were observed 
signiﬁ  cantly more frequently with haloperidol than with the 
other two study treatments. In addition, a number of ran-
domized studies have compared haloperidol monotherapy 
with olanzapine monotherapy (Shi et al 2002; Tohen et al 
2003), quetiapine (McIntyre et al 2005), risperidone (Segal 
et al 1998; Smulevich et al 2005), and aripiprazole (Vieta 
et al 2005a) in acute mania. The majority of these have 
demonstrated comparable response or remission rates with 
the atypical antipsychotic to haloperidol, with the exception 
of the aripiprazole study. However, response rates to halo-
peridol in this study were particularly low compared with 
other studies, because the deﬁ  nition of response included 
the requirement to stay on medication for 12 weeks. A meta-
analysis of these studies showed similar reduction of manic 
symptoms and comparable response rates for haloperidol 
and for the atypical antipsychotics, but lower dropout rates 
due to adverse events, lower incidence of extrapyramidal 
symptoms, and better control of depressive symptoms with 
the atypical antipsychotics (Scherk et al 2007).
Amisulpride is an atypical antipsychotic which has been 
suggested to show superior efﬁ  cacy to both haloperidol and 
risperidone in improving affective symptoms in patients with 
schizophrenia (Peuskens et al 2002) and for which there is 
some evidence for efﬁ  cacy in affective disorders (Montgomery 
2002). A prospective open-label study of amisulpride as 
add-on therapy to mood stabilizers in the treatment of acute 
mania reported by Vieta et al showed a 3-fold reduction in 
YMRS total scores after 6 weeks treatment with adjunctive 
amisulpride. Sixty-ﬁ  ve percent of patients were considered 
responders (at least 50% improvement of YMRS scores) and 
remission was achieved by 50% of patients (Vieta et al 2005b). 
Also, a longitudinal study evaluating relapse rates before 
and after the introduction of amisulpride in patients treated 
for bipolar I disorder showed a 3-fold reduction of relapse 
rates after the introduction of amisulpride (Carta et al 2006). 
Amisulpride also shows a low incidence of extrapyramidal 
side-effects (Leucht et al 2002) and less propensity to produce 
weight gain compared with some other atypical antipsychotic 
(Leucht et al 2002). Therefore, combination treatment with 
amisulpride and a mood-stabilizer may be of interest in the 
treatment of bipolar disorder. In order to test this hypothesis, 
we have performed a randomized, open-label clinical trial 
comparing amisulpride and valproate combination therapy 
with haloperidol and valproate combination therapy in the 
treatment of acute mania.
The primary objective of this study was to compare the 
effectiveness of valproate and amisulpride combination 
treatment with that of valproate and haloperidol combination 
treatment for 3 months in patients with type I bipolar disor-
der presenting with a manic episode. Secondary objectives 
were to evaluate the clinical and biological safety of the two 
combination treatments, to evaluate efﬁ  cacy after 3 weeks, 
and to assess patient satisfaction at 3 months.
Subjects and methods
Study design
This was a multinational, randomized, open-label, parallel-
group, comparative phase II study. The study duration 
was 3 months. The study was conducted in 27 centers in 
5 European countries (Czech Republic, France, Poland, 
Slovakia, and Spain) between May 2004 and June 2005.
Entry criteria
The study included subjects aged 18–65 years with a current 
diagnosis of bipolar I disorder according to DSM-IV-TR 
criteria (APA 2000). Subjects were required to be currently 
in a manic episode fulﬁ  lling DSM-IV-TR criteria and to 
have experienced at least 1 manic episode in the past. The 
total score on the Young Mania Rating Scale (YMRS; 
Young et al 1978) was to be at least 20, with a score of at 
least 3 for at least 2 of the following YMRS items: elevated 
mood, increased motor activity, energy, sleep, or content 
(grandiosity). The score on the severity scale of the Clinical 
Global Impression for Bipolar Disorder questionnaire 
(CGI-BP; Spearing et al 1997) was to be at least 5.
Women of childbearing age were expected to be using 
an effective method of contraception and all subjects had 
to be able to comply with the study protocol. Pregnant and 
breast-feeding women were excluded.
Subjects with antecedents of intolerance to benzamide 
drugs, haloperidol or valproate, contraindications to any of 
these drugs, with comorbidities that might affect implemen-
tation or interpretation of the study, with clinically relevant Neuropsychiatric Disease and Treatment 2008:4(3) 677
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abnormalities in biochemical (notably hypokalemia, trans-
aminases higher than twice the upper limit of normal, or 
bilurubin or alkaline phosphatase outside the normal range), 
hematological or electrocardiographic (in particular, heart 
rate 55 bpm, congenital QT prolongation, or QTc Bazett 
interval 450 ms in males and 470 ms in females) param-
eters, those having participated in a clinical trial within the 
previous 3 months, and subjects with current or recent sub-
stance abuse or dependence were not included in the study.
Treatment with ﬂ  uoxetine in the previous 4 weeks, with 
injectable long-acting antipsychotics if the interval between 
two injection periods had not elapsed at inclusion, with a 
mood stabilizer other than valproate at an effective dose for 
less than 7 days preceding the screening visit, and for whom 
a treatment switch was not justiﬁ  ed, was not allowed. Other 
prohibited drugs included Class Ia and Class III antiarryth-
mic drugs, beperidil, cisapride, sultopride, thioridrazine, 
erythromycin (iv), vincamine (iv), halofantril, pentamidine, 
and sparﬂ  oxacin.
Study procedures
Subjects fulﬁ  lling the entry criteria were randomized to 
receive either amisulpride and valproate or haloperidol 
and valproate. During the screening visit, the investiga-
tor contacted the contract research organization in charge 
of the operational management of the study by telefax in 
order to obtain a patient treatment number. Each number 
corresponded to one or other of the study treatments. Study 
medication was provided in numbered containers divided into 
separate packs containing sufﬁ  cient drug to last the patient 
between 2 consecutive study visits, the total quantity cover-
ing the entire study period. Randomization was stratiﬁ  ed by 
country and numbers allocated on a patient by patient basis 
rather than in blocks. The randomization code was generated 
and maintained centrally by the contract research organiza-
tion in charge of the operational management of the study. 
Patients were randomized into the study and allocated study 
treatment in a sequential order according to this list, in each 
country. The allocation sequence was not revealed before 
treatments had been assigned.
The treatment phase was preceded by a 3-day wash-out 
period which could be reduced to 1 day in case of aggrava-
tion of mania. The treatment phase lasted for 12 weeks. 
Subjects were hospitalized during the washout period and 
for at least the 2 ﬁ  rst weeks of the active treatment period; 
hospital discharge was decided when considered appro-
priate by the investigator. Study visits were scheduled on 
Day –3, Day 0, Day 4, Day 7, Week 2, Week 3, Week 8, and 
Week 12. Evaluations made at Week 3 and Week 12 were 
used for the efﬁ  cacy evaluation. A latitude of 3 days and 
7 days respectively was allowed for these study visits either 
side of the planned date. Additional visits could be made if 
considered appropriate by the investigator.
Treatment
Amisulpride was provided as scored 400 mg tablets (Solian®, 
Sanoﬁ  -Aventis, Paris, France) and haloperidol as scored 5 mg 
tablets. Valproate was provided as the pharmaceutical form 
approved for the treatment of bipolar disorder in participating 
countries (sustained-release sodium valproate + valproic acid 
tablets 500 mg for the Czech Republic, Poland, Slovakia, and 
Spain, or enteric-coated valproate semisodium tablets 500 mg 
or 250 mg in France). No blinding of study medication was 
attempted in order to simplify the procedures and to enrol a 
more representative sample. Treatment was initiated at a dose 
of 600 mg/day for amisulpride and 10 mg/day for haloperidol. 
In both cases, the starting dose of valproate used was that 
speciﬁ  ed in local prescribing recommendations (10–15 mg/kg 
in Czech Republic, 20 mg/kg/day in France, 5–15 mg/kg 
in Poland, 10–15 mg/kg in Slovakia, 20–30 mg/kg/day in 
Spain). From Day 4 onwards, the dose could be adjusted at 
the investigator's discretion at any study visit, as a function 
of the clinical state of the subject. For amisulpride, dose 
adjustment was made in steps of 200 mg within a range 
of 400–800 mg/day. For haloperidol, the adjustment was 
made in steps of 5 mg within a range of 5–15 mg/day. Dose 
adjustments were made on the day after the study visit and 
could be made as many times as deemed necessary. The dose 
of valproate could be adjusted accordingly if plasma levels 
were outside the 40–100 µg/mL range at the Week 3 study 
visit, or in case of emergence of side-effects. Otherwise, the 
dose of valproate was not changed during the course of the 
study. Treatment was pursued for 12 weeks.
At each study visit, the patient was expected to return the 
previous medication pack and receive a new one covering 
the period until the next study visit. A pill count of returned 
medication was made, and the number of returned pills 
recorded on a drug tracking form. On this basis, the investiga-
tor evaluated reported the overall compliance of the patients 
at each study visit on the case report form (yes or no).
Concomitant use of other psychotropic drugs was pro-
hibited, except for nonbenzodiazepine hypnotics in case 
of insomnia and lorazepam if needed to control agitation, 
irritability, restlessness, insomnia, and hostile behaviors. 
The maximum daily dose of lorazepam was 6 mg in the ﬁ  rst 
week and 2 mg in the second and third weeks. Thereafter Neuropsychiatric Disease and Treatment 2008:4(3) 678
Thomas and Vieta
benzodiazepine use was prohibited. Antiparkinsonian drugs 
(eg, biperiden or procyclidine or tropatepine) could be intro-
duced to control incapacitating extrapyramidal symptoms 
documented by the Simpson Angus Scale (Simpson and 
Angus 1970). The use of other drugs entering in the exclu-
sion criteria for the trial (eg, anti-arrhythmic drugs) was 
also prohibited.
Evaluation of effectiveness
The primary efﬁ  cacy criterion was the proportion of subjects 
fulﬁ  lling a combined criterion of response, deﬁ  ned as a 
reduction of at least 50% of the YMRS score, and completion 
of the 12-week treatment period. This outcome was chosen 
because the trial was aimed at assessing effectiveness, rather 
than pure efﬁ  cacy, and because it has been successfully 
used before (Vieta et al 2005a). Secondary efﬁ  cacy criteria 
included the proportion of responders at Weeks 3 and 12, the 
proportion of subjects in remission, deﬁ  ned as a YMRS score 
12, at study end, changes from baseline in YMRS score and 
Brief Psychiatric Rating Scale (BPRS; Overall and Gorham 
1962) score at Weeks 3 and 12, changes from baseline in the 
Montgomery and Åsberg Depression Rating Scale (MADRS; 
(Montgomery and Åsberg 1979)) and the Global Assessment 
Scale (GAS; Endicott et al 1976) at study end and the change 
item and patient satisfaction item of the CGI-BP at study end. 
The maintenance of response was evaluated by Kaplan-Meier 
survival analysis. A sustained response was deﬁ  ned as reach-
ing a YMRS score 12 and a MADRS score of 15 for at 
least 2 consecutive visits. Subjects switching to depression or 
relapsing into mania were identiﬁ  ed. A switch to depression 
was deﬁ  ned as an increase in the CGI-BP depression score 
of at least 2 points and a MADRS score 15. A relapse into 
mania was deﬁ  ned as an increase of at least 25% in the YMRS 
total score following a sustained response. A posthoc analysis 
of efﬁ  cacy was performed on patients with prominent psy-
chosis deﬁ  ned by a score of at least 3 for the “Content” item 
of the YMRS scale at D0, or a score of at least 4 for at least 2 
of the 5 following items of the BPRS scale at D0 (conceptual 
disorganization, grandiosity, suspiciousness, hallucinatory 
behavior, and unusual thought content). A second posthoc 
analysis was also performed on patients with depressive 
symptoms at inclusion deﬁ  ned by a score at baseline of at 
least 10 on the MADRS scale.
Evaluation of safety
Safety was assessed by recording spontaneously reported 
adverse events throughout the study. Adverse events were 
classiﬁ  ed according to severity and to presumed relationship 
with treatment. Extrapyramidal function was assessed with 
the Simpson Angus scale (SAS), the Barnes akathisia scale 
(Barnes 1989) at each study visit, and the Abnormal Invol-
untary Movement Scale (AIMS; NIMH 1976). Vital signs 
and body weight were measured at each visit. Standard 
laboratory tests were performed before the ﬁ  rst treatment 
administration, at Weeks 3, 8, and 12. Treatment compliance 
to treatment was assessed by the investigator by counting 
unused tablets.
Statistical analysis
The statistical analysis was designed to test the hypothesis 
that the effectiveness of combination treatment with amisul-
pride and valproate would be superior to that of combination 
treatment with haloperidol and valproate after 3 months. 
To this end, a priori power calculations were performed to 
determine the target population size. A difference between 
treatment groups in the proportion of subjects meeting the 
primary endpoint of 22% was considered to be the minimum 
clinically relevant difference based on a previous trial with 
aripiprazole (Vieta et al 2005a; Vieta and Carne 2005). It was 
estimated that, in order to have a power of 80% to demon-
strate such a difference with a one-tailed α-risk of 0.05, 60 
subjects should be included in each treatment arm.
Three study populations were considered. The safety 
population was defined as all subjects exposed to at 
least 1 dose of study medication. The intention-to-treat (ITT) 
population was deﬁ  ned as all randomized subjects who took 
at least one dose of study medication and provided at least 
one postbaseline efﬁ  cacy measure. The per protocol (PP) 
population was deﬁ  ned as those members of the ITT popu-
lation who did not present a major protocol violation. Since 
this was a superiority study, the ITT population was used for 
determination of effectiveness, as this is the most conserva-
tive assumption. Supportive analyses were performed on the 
PP population. Missing data were handled by the principle 
of last observation carried forward (LOCF).
Categorical variables were compared with the χ² test or 
Fisher's exact test and quantitative variables with the Wil-
coxon test or by analysis of variance (ANOVA). Two-tailed 
comparisons were performed throughout, with a probability 
(p) value of 0.05 taken as signiﬁ  cant. Statistical analyses 
were carried out using the SAS software package (Version 
8.2; SAS Institute, Cary, NC, USA).
Ethics
The study was conducted according to the Declaration of 
Helsinki (Hong Kong Amendment), Good Clinical Practices Neuropsychiatric Disease and Treatment 2008:4(3) 679
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(European Guidelines), and pertinent national legal and 
regulatory requirements. Written informed consent was 
obtained from each subject. Subjects were free to withdraw 
from the study at any time for any reason, without effect on 
their medical care. The protocol was submitted to and approved 
by the appropriate local ethics committee in each country.
Results
Study population
One hundred and twenty-six subjects were screened for 
inclusion and the 123 who fulﬁ  lled the entry criteria were 
randomized to 1 of the 2 treatment arms, 62 to amisulpride, 
and 61 to haloperidol. The median number of patients included 
by center was 5 (range: 1–25). Two subjects randomized to 
the haloperidol group never received the study medication 
and were excluded from the safety population. An additional 
subject in this group provided no postbaseline efﬁ  cacy data 
and was thus excluded from the ITT population. The ITT 
population thus consisted of 62 subjects in the amisulpride 
arm and 58 subjects in the haloperidol arm. Major protocol 
deviations were detected in 15 subjects in the amisulpride 
group and in 3 subjects in the haloperidol group, who were 
excluded from the PP population. The PP population corre-
sponded to 102 subjects overall, 75.8% of the group originally 
randomized to amisulpride and 90.2% of the group originally 
randomized to haloperidol. The major protocol violations 
detected mostly concerned deviations from the permitted time 
windows for study visits at Weeks 3 and 12 (10 violations in 
the amisulpride group and 2 in the haloperidol group) or use 
of prohibited psychotropic medication (6 in the amisulpride 
group; Table 1). Fifteen subjects in the amisulpride group and 
23 in the haloperidol group failed to complete the 12-week 
treatment period as planned, principally due to the occurrence 
of an adverse event (7 subjects in the amisulpride group and 
15 in the haloperidol group; Table 1). Subject ﬂ  ow through 
the study is presented in Figure 1.
The demographic and clinical characteristics of the ITT 
population are presented in Table 2. None of these variables 
differed signiﬁ  cantly between the two treatment groups, 
with the exception of mood state at entry. The mean age 
of the population was 43.6 ± 12.7 years and the majority 
(59.2%) were female. Overall, subjects had a long history 
of bipolar disorder (median disease duration: 11 years 
[range: 1–38 years]; median number of previous episodes: 
4 [range: 1–40]). At inclusion, the mood state was euphoric 
in all but 3 subjects in the amisulpride group and 14 in 
the haloperidol group. This was the only signiﬁ  cant inter-
group difference observed in the ITT population (p = 0.003; 
Fisher’s exact test). The mean mania score on the YMRS 
was 29.9. Psychiatric comorbidity was present in 9 subjects 
in each group, namely substance abuse (principally alcohol 
or cannabis) in 5 subjects in the amisulpride group and 7 in 
the haloperidol group, anxiety disorders in 5 and 2 subjects 
respectively (one amisulpride-treated subject presented 
both disorders).
Table 1 Major protocol violations and premature study 
discontinuations in the ITT population. Note that individual subjects 
may present more than one protocol violation or reason for 
discontinuation and the categories are thus not mutually exclusive
   Amisulpride  +   Haloperidol +
   valproate  valproate
   (N  = 62)  (N = 58)
Major protocol violations  15  3
  Week 3 visit time window  3  0
not respected
  Week 12 visit time window  7  2
not respected
  No BPRS data at baseline  –  1
  No GAS data at baseline  –  1
Use of prohibited psychotropic  6  0
medication (psychotropic
agents other than hypnotics and
benzodiazepines 72 hours)
Premature treatment  15  23
discontinuations
  Occurrence of an adverse  7  15
event
  Perceived lack of efﬁ  cacy  4  5
 Consent  withdrawn  3  6
 Poor  compliance  1  1
 Other  1  2
Abbreviations: BPRS, Brief Psychiatric Rating Scale GAS, Global Assessment Scale.
Figure 1 Subject ﬂ  ow diagram.
Abbreviations: ITT, intention to treat; PP, per protocol.
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The subgroup of patients with prominent psychosis 
consisted of 87 subjects (72.5% of the ITT population). At 
inclusion, the mean mania score on the YMRS in this sub-
group was 30.9, with mean scores for amisulpride (n = 46) 
and haloperidol (n = 41) of 30.8 and 31.1 respectively. The 
subgroup of patients with depressive symptoms at inclu-
sion deﬁ  ned by MADRS score of at least 10 consisted of 
50 patients with 23 patients in the amisulpride group and 27 
patients in the haloperidol group.
The majority of patients (all but 8 in the amisulpride 
group and 7 in the haloperidol group) had received psycho-
tropic medication in the previous 6 months. Eleven patients 
(9.2%) had received lithium, 15 (12.5%) carbamazepine 
or oxcarbazepine, and 52 (43.3%) valproate for control of 
mood disorders. The response to these treatments was not 
recorded. In addition, 58 patients (48.3%) had received 
atypical antipsychotics, 53 (44.2%) classical antipsychotics, 
49 (40.8%) benzodiazepines, 26 (21.7%) antidepressants, and 
17 (14.2%) nonbenzodiazepine hypnotics. No difference in 
previous psychotropic drug exposure was observed between 
treatment groups.
Exposure to medication
The dose of study medication evolved over the study, gen-
erally downwards. At the end of the study around half of 
subjects treated with amisulpride were receiving a dose of 
400 mg/day and over three-quarters of those in the halo-
peridol group were receiving a dose of 5 mg/day (Figure 2). 
However, the dose of amisulpride was increased to 800 mg in 
around one-ﬁ  fth of the subjects. Overall compliance to study 
medication was considered to be acceptable in all patients 
and at each study visit with the exception of 1 subject in the 
amisulpride group on Day 4, 3 subjects in the amisulpride 
group at Month 3, and 4 subjects in the haloperidol group 
at Month 3.
At Week 3, plasma concentrations of valproate were 
signiﬁ  cantly lower in the amisulpride group (64.5 µg/mL 
[95% conﬁ  dence intervals (CI): 57.2–71.9]) than in the 
haloperidol group (74.9 µg/mL [95% CI: 67.5–82.4]). 
However, this difference was no longer apparent at Week 
12 (amisulpride: 64.3 µg/mL [48.8–79.7]; haloperidol: 
69.2 µg/mL [61.9–76.6]).
For concomitant psychotropic medications taken by the 
patients during the course of the trial, no statistical differences 
were shown between the two treatment groups with regard to 
either benzodiazepine (p = 0.944) or hypnotic (p = 0.659) use. 
Authorized benzodiazepines were used by 58.3% of subjects 
at inclusion, with no difference between groups (35 subjects 
in each group). Benzodiazepine use declined thereafter over 
the course of the study. Antiparkinsonian drugs were pre-
scribed to 12 subjects (19.4%) in the amisulpride group and 
Table 2 Baseline demographic and clinical characteristics of 
subjects in the intention to treat population. Data for categorical 
variables are presented as numbers of subjects (%) and quantitative 
variables as mean ± standard deviation
   Amisulpride  +   Haloperidol + 
   valproate    valproate
   (N  = 62)  (N = 58)
Gender (female)  36 (58.1%)  35 (60.3%)
Age (years)  41.8 ± 12.9  45.4 ± 12.3
Body mass index (kg/m²)  26.3 ± 5.4  26.0 ± 4.9
Duration of bipolar disorder   12.2 ± 8.9  13.0 ± 8.8
(years)
Nr of previous episodes  7.2 ± 8.6  6.2 ± 5.5 
Nr of previous manic episodes  3.8 ± 5.0  4.5 ± 4.7 
Time since last episode (years)  1.8 ± 1.8  1.8 ± 2.1 
Type of the last episode
  Manic episode  41 (66.1%)  43 (74.1%)
  Hypomanic episode  1 ( 1.6%)  1 ( 1.7%) 
  Mixed episode  2 ( 3.2%)  1 ( 1.7%) 
  Major depressed episode  18 (29.0%)  13 (22.4%)
Psychiatric comorbidity  9 (14.5%)  9 (15.5%)
Past psychotropic drug usea  54 (87.1%)  51 (87.9%)
Previous hospitalization  51 (82.3%)  54 (93.1%)
Mood state at inclusion      
into study
  Dysphoric mania  3 (4.8%)  14 (24.1%)
  Euphoric mania  59 (95.2%)  44 (75.9%)
YMRS score  29.2 ± 5.2  30.5 ± 5.3
BPRS score  35.8 ± 9.4  37.7 ± 9.9
GAS score  43.5 ± 10.0  43.8 ± 11.2
MADRS score  8.7 ± 3.1  9.4 ± 3.7 
CGI-BP Severity score
 Mania  5.3  ± 0.5  5.4 ± 0.5
 Depression  1.2  ± 0.8  1.2 ± 0.6
 General  bipolar  4.8  ± 1.0  5.2 ± 0.9
aIn previous 6 months.
Abbreviations: BPRS, Brief Psychiatric Rating Scale; CGI-BP, Clinical Global Impres-
sion Bipolar Sale; GAS, Global Assessment Scale; MADRS, Montgomery and Åsberg 
Depression Rating Scale; YMRS, Young Mania Rating Scale.
Figure 2 Treatment dose at study end. Left: amisulpride; right: haloperidol.
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to 32 (54.2%) in the haloperidol group (see Safety section 
below).
Effectiveness
The primary outcome measure was the proportion of subjects 
who completed the 3-month study period and responded to 
treatment (50% reduction in YMRS score compared with 
baseline) in the ITT population. The number of subjects fulﬁ  ll-
ing this criterion was 45/62 (72.6%) in the amisulpride group 
and 38/58 (65.5%) in the haloperidol group. These proportions 
were not signiﬁ  cantly different (p = 0.402; χ² test). The cor-
responding ﬁ  gures for the PP population were 35/47 (74.5%) 
in the amisulpride group and 36/55 (65.5%) in the haloperidol 
group (p = 0.324; χ² test). In the subgroup of patients with 
prominent psychosis, the number of subjects fulﬁ  lling the 
primary endpoint was 35/46 (76.1%) in the amisulpride group 
and 27/41 (65.9%) in the haloperidol group, with no signiﬁ  cant 
difference between groups (p = 0.292; χ² test).
No signiﬁ  cant differences between treatment groups were 
observed for remission rates, response rates, or mean change 
in YMRS scores. At the end of the 12-week treatment period, 
52 subjects in the amisulpride group (83.9%) and 52 subjects 
in the haloperidol group (89.7%) were considered to be in 
remission (YMRS score 12); this difference was not statis-
tically signiﬁ  cant. Response rates at study end were 87.1% 
(54/62 subjects) in the amisulpride group and 93.1% (54/58 
subjects) in the haloperidol group. Mean YMRS scores 
declined rapidly in both groups with no obvious difference 
in the rate of response (Figure 3). During the course of the 
study 74.2% of the amisulpride group (46/62 subjects) and 
84.5% of the haloperidol group (49/58 subjects) achieved 
a sustained response. One subject in the amisulpride group 
and 6 subjects in the haloperidol group relapsed into mania 
after having achieved a sustained response, all of whom 
belonged to the subgroup of patients with prominent psy-
chosis. There was a trend toward a lower risk of relapse for 
patient treated by amisulpride during the 3-month treatment 
period (p = 0.055). A switch to depression was observed in 
6 subjects in the amisulpride group and in 10 subjects in the 
haloperidol group (p = 0.223). The percentage of subjects 
switching to depression was equivalent for subgroups of 
subject with a MADRS score at inclusion 10 or 10.
The mean change in YMRS score was comparable in the 
two treatment groups at both Week 3 and Week 12 (Table 3). 
Similarly, scores on all the other psychopathology rating 
scales improved to a similar extent in both treatment groups 
(Table 3). Changes on the depression item of the CGI-BP and 
the MADRS were, however, minimal. No statistically sig-
niﬁ  cant differences between treatment groups were identiﬁ  ed 
for any of these secondary end-points. However, a trend was 
observed for a greater decrease of MADRS scores between 
baseline and study end in the amisulpride group (mean per-
centage change in MADRS score: –27.5% vs –0.3%).
Around three-quarters of subjects considered them-
selves much improved or very much improved at study end 
(Figure 4). No signiﬁ  cant difference in CGI-BP Change item 
category distribution was observed between the two treat-
ment groups (χ² test).
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Figure 3 Young Mania Rating Scale scores over the course of the study in the intention to treat population. Data are presented as mean scores ± standard deviation. {: amisulpride 
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All patients could be discharged after 2 weeks, as 
speciﬁ  ed in the protocol, with the exception of 3 patients in 
the haloperidol group for whom continued hospitalization 
was considered necessary to manage depressive symptoms. 
One patient in the haloperidol group required rehospitaliza-
tion due to an emergent depressive mood episode while 
continuing medication, and 2 patients in the amisulpride 
group who had decided to stop treatment before the end of 
the study required rehospitalization due to an emergent mood 
episode (1 case of mania and 1 of depression). Two patients 
were rehospitalized for reasons other than mood disorders, 
a woman in the amisulpride group for breast cancer surgery, 
and a women in the haloperidol group for management of 
major anxiety related to extrapyramidal symptoms.
Safety
Treatment-emergent adverse events were reported in 76% of 
subjects overall (Table 4). Most (74.9%) of the 203 events 
reported were considered to be treatment-related. These 
events were reported more frequently in subjects in the halo-
peridol group than in the amisulpride group (p = 0.009; χ² 
test). The most frequently reported adverse events were extra-
pyramidal disorders, akathisia, depression and tremor. Extra-
pyramidal disorders, akathisia, tremor, hypersialorrhoea, 
and dyskinesia were reported more frequently in subjects 
receiving haloperidol, whereas fatigue, somnolence, and 
amenorrhoea were more frequent in the amisulpride group. 
Severe adverse events were more frequent in the haloperidol 
group (p = 0.004). Treatment was discontinued due to an 
adverse event in 7 subjects treated with amisulpride (1 case of 
sleepiness and 3 cases each of depression and extrapyramidal 
symptoms) and 15 subjects treated with haloperidol (9 cases 
of extrapyramidal symptoms, 5 cases of depression, and 1 
case of rash). In 1 patient treated with haloperidol, the dose 
was reduced to 2.5 mg in order to control excessive drooling 
and the drug subsequently discontinued due to the emer-
gence of depression. Serious adverse events were reported 
in 3 subjects in the amisulpride group (1 case each of breast 
cancer, depression and mania) and in 5 subjects (1 case each 
of cytolytic hepatitis and anxiety and 3 cases of depression) 
in the haloperidol group. No severe or serious adverse events 
were considered to be related to treatment in the amisulpride 
group. No deaths were reported during the study.
Scores on the Simpson-Angus Scale increased signiﬁ  cantly 
over the course of the treatment period in both groups (Table 5). 
However, the extent of the increase was signiﬁ  cantly higher 
Table 3 Changes in rating scale scores over the study period in the ITT population. Data are presented as mean values ± standard 
deviation of change from baseline
 Amisulpride  + valproate (N = 62)  Haloperidol + valproate (N = 58)  p (ANCOVA)
YMRS score (mean change)     
 Week  3  –20.5  ± 8.4  –22.2 ± 9.1  0.671 (NS)
 Week  12  –23.0  ± 10.4  –25.6 ± 9.3  0.309 (NS)
BPRS score (mean change)     
 Week  3  –11.3  ± 8.7  –13.7 ± 9.3  0.312 (NS)
 Week  12  –12.0  ± 11.1  –13.9 ± 10.4  0.694 (NS)
GAS score (mean change)     
 Week  12  34.2  ± 20.2  31.1 ± 21.1  0.420 (NS)
MADRS score (mean change)     
 Week  12  –3.2  ± 8.1  –1.1 ± 9.9  0.094 (NS)
CGI-BP score (mean change)     
 Mania  –3.6  ± 1.3  –3.8 ± 1.2  0.318 (NS)
 Depression  0.3  ± 1.2  0.5 ± 1.3  0.269 (NS)
 General  bipolar  –2.6  ± 1.8  –3.0 ± 1.8  0.230 (NS)
Abbreviations: BPRS, Brief Psychiatric Rating Scale; CGI-BP, Clinical Global Impression Bipolar Sale; GAS, Global Assessment Scale; MADRS, Montgomery and Åsberg 
Depression Rating Scale; YMRS, Young Mania Rating Scale; NS, nonsigniﬁ  cant.
Figure 4 Improvement over the course of the study in the intention to treat population. 
Patient satisfaction questionnaire. Grey bars: much improved; black bars: very much 
improved.
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in the haloperidol treatment group. The difference in change 
from baseline between the two treatment groups was –2.514 
(95% CI: –3.965; –1.062]. Similarly, the increase in score on 
the Barnes akathisia index was also signiﬁ  cantly higher in 
the haloperidol group (Table 5). For the AIMS, an increase 
in mean scores was observed in the haloperidol group but 
not in the amisulpride group (Table 5). The difference in 
change from baseline between the two treatment groups 
for the AIMS score was –0.901 (95% CI: –1.737; –0.065). 
Antiparkinsonian drugs were considered to be required for 
12 subjects in the amisulpride group and for 32 in the halo-
peridol group (Table 5).
Potentially clinically signiﬁ  cant abnormalities in liver 
enzymes and electrolytes were observed in a minority of 
subjects (Table 6). Potentially signiﬁ  cant changes in blood 
pressure or heart rate were observed in 15 subjects (7 treated 
with amisulpride and 8 treated with haloperidol), most 
commonly orthostatic hypotension (10 subjects). Clinically 
signiﬁ  cant weight gain (7% from baseline) was observed 
in 5 subjects receiving amisulpride and in two receiving 
haloperidol. In addition, one haloperidol-treated subject 
lost a signiﬁ  cant amount of weight (7.8 kg). None of these 
ﬁ  ndings was identiﬁ  ed as serious adverse events and none 
led to treatment discontinuation.
Discussion
This randomized, controlled study in acute mania demon-
strated that combination treatment with valproate and either 
amisulpride or haloperidol led to a treatment response rate of 
72.6% and 65.5% respectively over a 12-week study period. 
The incidence of adverse events in general and of extrapyra-
midal symptoms in particular was lower in the amisulpride 
group than in the haloperidol group.
The study used a composite primary efﬁ  cacy outcome 
measure combining antimanic treatment response and study 
completion, because the extent of adherence to protocols in 
clinical trials in acute mania can be very low, with more than 
50% of premature study discontinuations in some studies 
(Licht 2001, 2002). This renders the ﬁ  ndings of such trials 
difﬁ  cult to interpret, particularly when using classical meth-
ods for managing missing data such as LOCF. Restricting the 
analysis to subjects who complete the study thus increases 
the robustness of the results. Nonetheless, in the present 
study, discontinuation rates were relatively low, 24% in the 
Table 4 Treatment-emergent adverse events reported in the Safety populationa
 Amisulpride  + valproate (N = 62)  Haloperidol + valproate (N = 59)  p
TEAEs 41  (66.1%)  51  (86.4%)  0.009
TEAEs related to study treatment  34 (54.8%)  48 (81.4%)  0.002
Severe TEAEs  2 (3.2%)  12 (20.3%)  0.004
Severe TEAEs related to study treatment  None  12 (20.3%)  0.001
TEAEs resulting in discontinuation  7 (11.3%)  15 (25.4%)  0.044
Serious TEAEs  3 (4.8%)  5 (8.5%)  0.484 (NS)
Serious TEAEs related to study treatment  None  4 (6.8%)  0.054 (NS)
aData are presented as number of subjects (%).
Abbreviations: TEAEs, treatment-emergent adverse events; NS, nonsigniﬁ  cant.
Table 5 Measures of extrapyramidal function in the Safety populationa
 Amisulpride  + valproate (N = 62)  Haloperidol + valproate (N = 59)  p
Simpson-Angus Scale     
  Baseline  0.4 (0.17; 0.70)  1.1 (0.33; 1.94)  0.001 (ANOVA)
  Endpoint  1.6 (0.86; 2.35)  4.8 (3.37; 6.26) 
  Change  1.2 (0.46; 1.87)  3.7 (2.38; 4.98) 
Barnes Akathisia Index     
  Baseline  0.0 (–0.01; 0.10)  0.2 (0.05; 0.32)  0.001 (t-test)
  Endpoint  0.1 (0.01; 0.25)  0.7 (0.44; 1.02) 
AIMS score     
  Baseline  0.3 (0.04; 0.63)  1.0 (0.29; 1.68)  0.035 (ANOVA)
  Endpoint  0.2 (0.01; 0.41)  1.8 (0.61; 2.93) 
 Change  –0.1  (−0.35; 0.09)  0.8 (–0.08; 1.62) 
  Use of antiparkinsonian medication  12 (19.4%)  32 (54.2%)  0.001 (χ² test)
aData are presented as mean values with 95% conﬁ  dence intervals.
Abbreviation: AIMS, Abnormal Involuntary Movement Scale.Neuropsychiatric Disease and Treatment 2008:4(3) 684
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amisulpride group and 38% in the haloperidol group. Since 
the emergence of adverse events was the principal driver of 
nonadherence, the better-tolerated amisulpride was associ-
ated with better adherence. This has important consequences 
for effectiveness of treatment in everyday clinical practice 
where patient follow-up may be less intensive than in a 
randomized clinical trial.
The response rate in the haloperidol group from this 
study was similar to that observed in the combination treat-
ment group (70%) in a previous study of haloperidol or 
perazine combined with valproate versus valproate alone 
(Muller-Oerlinghausen et al 2000). The decrease in YMRS 
score observed was rather larger than that reported for the 
haloperidol group in a study of adjunctive risperidone ver-
sus haloperidol in combination with lithium or valproate 
(Sachs et al 2002). Treatment responses in the amisulpride 
and valproate group were of comparable magnitude to those 
reported in previous trials of other atypical antipsychotics 
combined with lithium or valproate in the treatment of acute 
mania (Sachs et al 2002, 2004; Tohen et al 2002; Yatham 
et al 2004).
Comparable efﬁ  cacy between the two treatment groups 
was observed across all efficacy end-points evaluated, 
supporting the robustness and consistency of the ﬁ  ndings. 
Although superiority of amisulpride over haloperidol was 
not demonstrated, both drugs had notably high response 
rates. In a comparative study of olanzapine and haloperidol 
(Tohen et al 2003), olanzapine did not differ from haloperidol 
in achieving overall remission of bipolar mania. In another 
monotherapy trial, comparing aripiprazole with haloperidol, 
the atypical antipsychotic did prove to be superior using 
the same measure of effectiveness as this one (Vieta et al 
2005a). However, in this study anticholinergic medication 
was not allowed and this caused a high number of drop-outs 
in the haloperidol arm, thus reducing the number of patients 
achieving the end-point.
No difference between treatments in terms of switch 
to depression or relapse into mania was observed, which 
concerned a relatively small number of subjects (no more 
than 10 per group). However, the frequency of switch to 
depression appeared to be in favor of the amisulpride group 
(11.3% vs 19.0%). Switch to depression in either treatment 
group was independent of baseline MADRS depression 
symptoms scores. Given the potential antidepressant effect 
of amisulpride observed in other patient groups (Montgomery 
2002; Peuskens et al 2002), this merits a dedicated study in 
bipolar depression.
The difference between the two treatment groups in 
terms of extrapyramidal symptoms is consistent with what 
is known of the comparative tolerability of amisulpride and 
haloperidol in schizophrenia. Antiparkinsonian medication 
was required by 55.2% of subjects receiving haloperidol 
compared to 19.4% of those receiving amisulpride. These 
data can be compared with the proportions of patients 
requiring such medication in the risperidone (17%) 
and haloperidol (38%) arms of the earlier valproate 
combination study of these drugs (Sachs et al 2002). 
There was no obvious speciﬁ  c tolerability issue associated 
with amisulpride treatment. The adverse event proﬁ  le of 
amisulpride was consistent with that described in clinical 
trials in patients with schizophrenia (Rein et al 2000). 
Overall, the observation of similar efﬁ  cacy to haloperidol, 
with improved tolerability, is consistent with data from 
clinical trials comparing other atypical antipsychotics to 
haloperidol in acute mania (Scherk et al 2007).
Concerns have been raised about the poor generaliz-
ability of many trials in the ﬁ  eld of bipolar disorder (Vieta 
and Carne 2005). This trial tried to overcome such concerns 
with a pragmatic design which imposed fewer constraints on 
patients and stipulated less stringent entry criteria. Anticho-
linergic drugs were thus allowed, and all patients received 
valproate. Nonetheless, inspection of the characteristics of 
included patients revealed that the patients were typically 
middle-aged, with a mean duration of illness of 12.6 years 
and experiencing relatively frequent and recent mood epi-
sodes. Typically, patients had been previously treated with, 
and presumably responded to, valproate rather than lithium. 
It will be important to determine whether the results can 
be replicated in patients who are responsive to lithium, in 
Table 6 Potentially clinically signiﬁ  cant abnormalities in biochemical 
parameters in the Safety population
 Amisulpride  + Haloperidol  + 
 valproate    valproate 
 (N  = 62)  (N = 59)
Aspartate aminotransferase   − 1
2 × ULN
Alanine aminotransferase   1  2
2 × ULN
γ-Glutamyltransferase   2  3
2 × ULN
Alkaline phosphatase   − 1
1.5 × ULN
Potassium 3 mmol/L or   − 1
5.5 mmol/L
Total bilirubin ULN 10  3
Conjugated bilirubin ULN 8  4
Abbreviation: ULN, upper limit of normal.Neuropsychiatric Disease and Treatment 2008:4(3) 685
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patients with earlier disease, and in patients not treated with 
a mood stabilizer.
The study has a number of limitations. Firstly, the 
absence of a placebo group precludes estimation of the 
absolute size of the treatment effect. However, the adoption 
of a placebo arm may limit inclusion into the study to less 
severely ill patients and thus restrict the generalizability of 
the ﬁ  ndings (Vieta and Carne 2005). This limitation needs 
to be addressed in future studies by comparing outcome in 
patients receiving mood stabilizers alone with that in patients 
treated with mood stabilizers and adjunctive amisulpride 
treatment. Secondly, the open design introduces possible bias 
from the expectations of patients or investigators, although 
randomization should to some extent reduce the potential 
sources of bias inherent in open studies. Thirdly, although 
it matched what was anticipated in the a priori power 
calculations, the sample size was rather small, particularly 
considering the rates of premature study discontinuation 
(31.7%) and of major protocol violations (15.0%). For 
this reason, potentially relevant trends towards inter-group 
differences in secondary outcome measures, such as relapse 
into a new manic episode or change in depressive symptoms, 
could not be conﬁ  rmed. In future studies of this type, it would 
be important to include more patients per group in order to 
address a wider variety of outcome measures. A related 
limitation concerns the duration of the study. Although a 
12-week duration conforms to contemporary methodological 
guidelines for clinical trial design in acute mania (European 
Medicines Agency 2007) and seems justiﬁ  ed in an initial 
study, it does not allow the potential long-term beneﬁ  t of 
treatment in preventing future mood episodes. A longer 
study duration would be necessary to conﬁ  rm or refute the 
observed trend towards more effective relapse prevention 
in patients receiving amisulpride.
To our knowledge, this is the ﬁ  rst randomized compara-
tive study of amisulpride for the treatment of acute mania. 
Although the size and goals of the study were relatively 
modest, it yielded encouraging information on the potential 
beneﬁ  t provided by amisulpride in this patient population 
and opens perspectives for future studies aimed at clarifying 
the role of this antipsychotic in the treatment of mania. As 
well as benchmarking the treatment effect size for mono-
therapy with mood stabilizers, or possibly for other atypical 
antipsychotic drugs, such studies should address the use 
of amisulpride for preventing manic relapse, efﬁ  cacy for 
functional outcome, and quality of life, collection of data 
for relatives or carers, and possible differential efﬁ  cacy in 
different patient groups.
In conclusion, this study suggests that combination 
treatment with amisulpride and valproate represents a 
relatively effective and well-tolerated treatment option for 
acute mania.
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